Profiling Cisplatin Resistance in Head and Neck Cancer: A Critical Role of the VRAC Ion Channel for Chemoresistance.
HNSCC
chemotherapy resistance
drug transporter
personalized medicine
tumor therapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
27 Sep 2021
27 Sep 2021
Historique:
received:
19
08
2021
revised:
23
09
2021
accepted:
24
09
2021
entrez:
13
10
2021
pubmed:
14
10
2021
medline:
14
10
2021
Statut:
epublish
Résumé
Treatment success of head and neck cancers (HNSCC) is often hindered by tumor relapses due to therapy resistances. This study aimed at profiling cisplatin resistance mechanisms and identifying biomarkers potentially suitable as drug targets and for patient stratification. Bioinformatic analyses of suggested resistance factors in a cohort of 565 HNSCC patients identified the VRAC ion channel as a clinically relevant indicator for recurrent diseases following radiochemotherapy (
Identifiants
pubmed: 34638315
pii: cancers13194831
doi: 10.3390/cancers13194831
pmc: PMC8508519
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Cell Calcium. 2020 Nov;91:102258
pubmed: 32736154
Science. 2014 May 9;344(6184):634-8
pubmed: 24790029
J Pharmacol Exp Ther. 2006 Nov;319(2):879-86
pubmed: 16914559
Annu Rev Pathol. 2017 Jan 24;12:245-275
pubmed: 27959635
Nat Biotechnol. 2020 Jun;38(6):675-678
pubmed: 32444850
Exp Dermatol. 2018 Dec;27(12):1352-1360
pubmed: 30252954
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
J Inorg Biochem. 2016 Jul;160:287-95
pubmed: 27112899
Oncogenesis. 2017 Aug 28;6(8):e373
pubmed: 28846078
Cancers (Basel). 2011 Mar 15;3(1):1351-71
pubmed: 24212665
Oncogene. 2012 Apr 12;31(15):1869-83
pubmed: 21892204
Oncol Res Treat. 2017;40(6):328-332
pubmed: 28531899
Oncogene. 2016 Jun 30;35(26):3351-64
pubmed: 26657154
Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14298-302
pubmed: 12370430
J Physiol. 2000 Dec 1;529 Pt 2:385-94
pubmed: 11101648
Br J Cancer. 2011 Feb 15;104(4):593-8
pubmed: 21285987
EMBO J. 2015 Dec 14;34(24):2993-3008
pubmed: 26530471
Cell Death Dis. 2019 Jul 15;10(8):540
pubmed: 31308358
EBioMedicine. 2019 Oct;48:100-116
pubmed: 31597595
Nature. 2007 Feb 8;445(7128):661-5
pubmed: 17251932
Nanoscale. 2018 Jan 18;10(3):1453-1463
pubmed: 29303193
Am J Physiol Cell Physiol. 2016 Jun 1;310(11):C857-73
pubmed: 26984736
Cancer Sci. 2013 Mar;104(3):369-74
pubmed: 23216802
Oncotarget. 2012 Jan;3(1):31-43
pubmed: 22289787
PLoS One. 2010 Jan 29;5(1):e8960
pubmed: 20126410
PLoS One. 2013;8(1):e55540
pubmed: 23383219
Biol Chem. 2021 Aug 27;:
pubmed: 34450690
Aging (Albany NY). 2016 Jun;8(6):1236-49
pubmed: 27295551
Cancer Res. 2007 Jul 1;67(13):5999-6002
pubmed: 17616652
Beilstein J Nanotechnol. 2014 Aug 27;5:1380-92
pubmed: 25247121
Mol Cancer Ther. 2004 Dec;3(12):1543-9
pubmed: 15634647
Nanomaterials (Basel). 2020 Feb 22;10(2):
pubmed: 32098406
Int J Nanomedicine. 2019 Jun 06;14:4187-4209
pubmed: 31289440
Br J Cancer. 1993 Jun;67(6):1171-6
pubmed: 8512802
Adv Mater. 2009;21:419-424
pubmed: 19606281
Cell Cycle. 2007 Mar 1;6(5):518-21
pubmed: 17361097
Cancer Res. 2012 Jun 1;72(11):2912; author reply 2913
pubmed: 22593195
Curr Treat Options Oncol. 2017 Jul;18(7):40
pubmed: 28555375
Biochemistry (Mosc). 2000 Jan;65(1):95-106
pubmed: 10702644
NPJ Sci Food. 2018;2(1):22
pubmed: 30882042
Oncol Rep. 2018 Sep;40(3):1275-1286
pubmed: 30015914
Cancer Lett. 2015 Dec 1;369(1):20-7
pubmed: 26341688
EMBO Mol Med. 2014 Jan;6(1):66-79
pubmed: 24178749
Nat Rev Cancer. 2009 Feb;9(2):95-107
pubmed: 19165225
J Clin Oncol. 2015 Oct 10;33(29):3305-13
pubmed: 26351341
Pflugers Arch. 2016 Mar;468(3):385-93
pubmed: 26635246
Cancers (Basel). 2020 Nov 13;12(11):
pubmed: 33202816
Int J Oncol. 2018 Dec;53(6):2758-2768
pubmed: 30272277
JCI Insight. 2018 Aug 23;3(16):
pubmed: 30135305
Cell Death Dis. 2019 Dec 5;10(12):925
pubmed: 31804464
Cell Rep. 2014 Jul 10;8(1):40-9
pubmed: 24953650
Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3497-504
pubmed: 7909602
Eur J Cancer. 2017 Sep;83:258-265
pubmed: 28756138